RESUMO
Transgenic mice have been developed that express exclusively human sickle cell beta hemoglobin and have major pathological features found in humans with sickle cell disease. These mice provide a unique opportunity to investigate the fundamental mechanisms of this disease and to design new strategies to correct the associated genetic defect(s). We found that in breeding males expressing only adult human alpha-globin and sickle beta-globin (homozygous SS mice) with females containing these transgenes plus one copy of the mouse beta-globin gene (hemizygous SS mice) greater than expected numbers of hemizygous offspring were produced than homozygous mice (carrying no mouse beta-globin gene). These hemizygous mice, expressing the human alpha and sickle beta(s) transgenes in combination with mouse beta+/-, were used for our preliminary studies of their renal pathology. No kidney lesions were found in the control (129/Sv) mice, whereas about 50% of the hemizygous SS mice showed mild-to-severe kidney lesions, including glomerulonephritis, cystic atypical hyperplastic tubules, and general nephropathy. Kidneys of some hemizygous mice were normal or showed minimal nephropathy, yet those of the susceptible phenotype developed a mild-to-more-severe form of renal lesions. The tubular epithelium of kidneys of hemizygous mice of the more affected phenotype exhibited increased expression of inducible nitric oxide synthase with an increased 3-nitrotyrosine in close proximity. There was also a stronger immunostaining for vascular cell adhesion molecule-1 in the interstitial capillary cells as well as the tubular epithelial cells of the renal cortex, compared with normal control mice. The occurrence of a high incidence of renal abnormalities in our hemizygous SS mice suggests that these mice may provide a suitable model to study the pathogenesis of nephropathy resulting from altered blood flow and/or insufficient oxygen delivery.
Assuntos
Anemia Falciforme/patologia , Rim/patologia , Tirosina/análogos & derivados , Anemia Falciforme/genética , Anemia Falciforme/metabolismo , Animais , Imuno-Histoquímica , Rim/química , Masculino , Camundongos , Óxido Nítrico/biossíntese , Óxido Nítrico Sintase/análise , Óxido Nítrico Sintase Tipo II , Tirosina/análise , Molécula 1 de Adesão de Célula Vascular/análiseRESUMO
We found previously that the nitric oxide donor DEA/NO enhanced lipid peroxidation, DNA fragmentation, and cytotoxicity in human bronchial epithelial cells (BEAS-2B) when they were cultured in LHC-8 medium containing the superoxide-generating system hypoxanthine/xanthine oxidase (HX/XO). We have now discovered that DEA/NO's prooxidant action can be reversed by raising the L-tyrosine concentration from 30 to 400 microM. DEA/NO also protected the cells when they were cultured in Dulbecco's Modified Eagle's Medium (DMEM), whose standard concentration of L-tyrosine is 400 microM. Similar trends were seen with the colon adenoma cell line CaCo-2. Since HPLC analysis of cell-free DMEM or LHC-8 containing 400 microM L-tyrosine, DEA/NO, and HX/XO revealed no evidence of L-tyrosine nitration, our data suggest the existence of an as-yet uncharacterized mechanism by which L-tyrosine can influence the biochemical and toxicological effects of reactive nitrogen species.
Assuntos
Hidrazinas/farmacologia , Doadores de Óxido Nítrico/farmacologia , Óxido Nítrico/farmacologia , Superóxidos/antagonistas & inibidores , Superóxidos/toxicidade , Tirosina/farmacologia , Brônquios/citologia , Brônquios/efeitos dos fármacos , Células CACO-2/efeitos dos fármacos , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Dano ao DNA , Sinergismo Farmacológico , Humanos , Hidrazinas/toxicidade , Hipoxantina/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Óxido Nítrico/toxicidade , Doadores de Óxido Nítrico/toxicidade , Óxidos de Nitrogênio , Espécies Reativas de Oxigênio/metabolismo , Superóxidos/metabolismo , Xantina Oxidase/metabolismoRESUMO
Diazeniumdiolates are compounds containing the X-[N(O)NO](-) structural unit that as a class offer many advantages as tools for probing the roles of nitric oxide (NO) in biological redox processes. Available examples in which X is a secondary amine group spontaneously generate up to two molecules of NO per [N(O)NO](-) unit when dissolved in aqueous media; their half-lives range from 2 s (for X = L-prolyl) to 20 h [for X = (H(2)NCH(2)CH(2))(2)N] at pH 7. 4 and 37 degrees C, and are in general relatively little influenced by medium effects or metabolism. When X = O(-) (Angeli's salt), first-order dissociation produces NO(-) rather than NO, but the ion becomes an NO source on 1-electron oxidation; diazeniumdiolate-derived NO can also be used to generate reactive nitrogen/oxygen species with higher nitrogen oxidation states (+3 and +4) in the presence of selected oxidizing agents. The advantages of diazeniumdiolates in biomedical research are briefly illustrated with examples from the recent literature probing NO's role in inhibiting oxidative drug metabolism, radical-induced lipid oxidation, the cytotoxicity of reactive oxygen species, and ischemia-induced vascular reoxygenation injury. Future work with this compound class should provide further insight into the mechanisms of NO's involvement in pro- and antioxidant processes, and may well lead to important medicinal advances, including reversal of cerebral vasospasm and radiosensitization of hypoxic tumors.
Assuntos
Doadores de Óxido Nítrico/farmacologia , Compostos Nitrosos/farmacologia , Animais , Antioxidantes/química , Antioxidantes/farmacologia , Morte Celular/efeitos dos fármacos , Inibidores das Enzimas do Citocromo P-450 , Humanos , Técnicas In Vitro , Lipoproteínas LDL/metabolismo , Óxido Nítrico/química , Óxido Nítrico/farmacologia , Doadores de Óxido Nítrico/química , Compostos Nitrosos/química , Oxidantes/química , Oxidantes/farmacologia , Oxirredução , Espécies Reativas de Oxigênio/metabolismoRESUMO
Clindamycin's three-dimensional structure is shown via a computer rendered stereomodel to be strikingly similar to L-Pro-Met and the D-ribosyl ring of adenosine. This discovery has important implications for the rational design of new licosamides and for efforts to understand how this and related classes of agents selectively inhibit protein biosynthesis on the prokaryotic ribosome.
Assuntos
Clindamicina/química , Inibidores Enzimáticos/química , Peptidil Transferases/antagonistas & inibidores , Clindamicina/farmacologia , Desenho de Fármacos , Inibidores Enzimáticos/farmacologia , Modelos Moleculares , Estrutura Molecular , Inibidores da Síntese de Proteínas/química , Inibidores da Síntese de Proteínas/farmacologia , Relação Estrutura-AtividadeRESUMO
The folate compound 10-formyldihydrofolate (H2folate) has not been found as a component of intracellular folates in normal tissues but has been identified in the cytosol of methotrexate (MTX)-treated MCF-7 breast cancer cells and normal human myeloid precursor cells. Its identity was verified by coelution of this compound with a synthetic marker on high pressure liquid chromatography, its reduction to 10-formyltetrahydrofolate (H4folate) in the presence of dihydrofolate reductase, and its enzymatic deformylation to dihydrofolate in the presence of aminoimidazolecarboxamide ribonucleotide (AICAR) transformylase. Chemically synthesized monoglutamated or pentaglutamated 10-formyl-H2folate was examined for its interaction with three folate-dependent enzymes: AICAR transformylase, glucinamide ribotide (GAR) transformylase, and thymidylatesynthase. 10-Formyl-H2folate-Glu5 was a competitive inhibitor of thymidylate synthase (Ki = 0.16 microM with 5,10-methylene-H4folate-Glu1 as substrate and 1.6 microM with 5,10-methylene-H4folate-Glu5) and inhibited GAR transformylase (Ki = 2.0 microM). It acted as a substrate for AICAR transformylase (Km = 5.3 microM), and its efficiency was equal to that of the natural substrate 10-formyl-H4folate-Glu5. The inhibition of thymidylate synthase by 10-formyl-H2folate was highly dependent on the inhibitor's polyglutamation state, the -Glu5 derivative having a 52-85-fold greater affinity as compared to the affinity of -Glu1. Polyglutamation of 10-formyl-H2folate did not affect its inhibition of GAR transformylase. While the actual role of 10-formyl-H2folate contributing to the cytotoxicity of MTX has not been determined, this compound has the potential to enhance inhibition of GAR transformylase and thymidylate synthase, and at the same time provides additional substrate for AICAR transformylase. The MTX-induced intracellular accumulation of 10-formyl-H2folate and H2folate may play a role in the drug-related cytotoxicity through the contribution of these folates to the inhibition of thymidylate synthase and de novo purine synthesis.
Assuntos
Aciltransferases/metabolismo , Ácido Fólico/análogos & derivados , Hidroximetil e Formil Transferases , Metotrexato/farmacologia , Neoplasias da Mama , Linhagem Celular , Cromatografia Líquida de Alta Pressão , Citosol/metabolismo , Feminino , Ácido Fólico/síntese química , Ácido Fólico/isolamento & purificação , Ácido Fólico/metabolismo , Humanos , Cinética , Fosforribosilaminoimidazolcarboxamida Formiltransferase , Espectrofotometria UltravioletaRESUMO
Recently, folate-dependent enzymes in the de novo thymidine and purine biosynthetic pathways have come under scrutiny as potential sites for chemotherapeutic exploitation by antifolates. In this manuscript we report on the progress that has been made in designing inhibitors of these pathways. In addition, a molecular model is proposed for the design of new antifolates directed against thymidylate synthase (TS).